Friday Satellite Symposia
ASH is looking forward to Friday Satellite Symposia (FSS) in 2021! More information about the program, updated FSS Guidelines and how to apply will be available in February. FSS are industry-supported, CME-certified symposia . These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company.
The 2020 FSS were broadcast live on, Friday, December 4 according to the schedule below. Not all sessions are available on demand yet, but you may refer to individual listings of sessions for information on their future availability as determined by each corporate host. Virtual programs will be available on demand after the scheduled presentation, and according to the release information listed under each session, for a period of 1 week up to 90 days.
ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs. Please review the official FSS guidelines to learn about hosting a symposium.
For more information, contact Kelly Cade, ASH FSS Manager, Consultant, at fss@hematology.org.
1
Morning Symposia
7:00 a.m. - 10:00 a.m.
Pacific timeConsensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Multiple Myeloma (Part 1 of a 4-Part Series)
This program is supported by Abbvie Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm, Oncopeptides, Sanofi Genzyme and Takeda Oncology
Friday, December 04, 2020
This activity, the first of a 4-part live webinar series, will feature 5 multiple myeloma (MM) investigators serving as faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to the live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions & scenarios related to the management of MM. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.
7:00 a.m. - 10:00 a.m. Pacific timeFor more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.
On demand activity expected to be available here mid-January 2021.
Chair:
Neil Love, MD
Research To Practice
Miami, FLSpeakers:
Rafael Fonseca, MD
Division of Hematology and Oncology, Mayo Clinic
Scottsdale, AZOla Landgren, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NYNikhil C. Munshi, MD
Dana-Farber Cancer Institute
Boston, MARobert Z. Orlowski, MD,PhD
The University of Texas MD Anderson Cancer Center
Houston, TXEdward A. Stadtmauer, MD, FACP
Lymphoma Program, Abramson Cancer Center, University of Pennsylvania
Philadelphia, PASylvia Eriksen , Research To Practice
Email: bmoss@researchtopractice.comMastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine
This program is supported by Cleveland Clinic & AAMDS
Friday, December 04, 2020
The Cleveland Clinic Taussig Cancer Institute and AA & MDS International Foundation join together to present the symposium, Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine. This CME-certified activity provides an in-depth and up-to-date review of research related to the management and treatment strategies for patients with MDS, AML, myeloproliferative neoplasms, and myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.
7:00 a.m. - 10:00 a.m. Pacific timeOn demand activity expected to be available here in January 2021. For program questions, please contact: pringls@ccf.org
Chair:
Bhumika J. Patel, MD
Cleveland Clinic
Cleveland, OHSpeakers:
Kelly L. Bolton, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NYVikas Gupta, MD, FRCP, FRCPath
Princess Margaret Cancer Centre, University Health Network
Toronto, ON, CanadaBetty K. Hamilton, MD
Cleveland Clinic Foundation
Cleveland, OHJeffrey E. Lancet, MD
H. Lee Moffitt Cancer Center & Research Institute
Tampa, FLJaroslaw P. Maciejewski, MD, PhD
Cleveland Clinic
Cleveland, OHGuillermo F Sanz, MD, PhD
Hematology Department, Hospital Universitario y Politécnico La Fe
Valencia, SpainSamantha Pringle , Cleveland Clinic
Email: pringls@ccf.org2
Early Afternoon Symposia
11:00 a.m. - 2:00 p.m.
Pacific timeAccelerating Toward a Cure for Myeloma: Emerging Data, New Agents, and an Evolving Treatment Paradigm
This program is supported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm & Oncopeptides. Provided by the Annenberg Center for Health Sciences at Eisenhower. In partnership with Clinical Care Options, LLC & the International Myeloma Foundation.
Friday, December 04, 2020
Attendees of this annual International Myeloma Foundation/Clinical Care Options cosponsored program can expect to gain practical insights from a panel of experts as they discuss new therapeutic advances along with their personal approaches for myeloma care. This international panel will focus on evolving worldwide standards of care and will also provide their perspectives on promising agents that may soon change practice. As part of panel discussion, the experts will debate clinical questions, review available evidence and challenges that affect therapeutic decisions, and then share their individual treatment recommendations for each case. Throughout the program, learners will be able to vote on case scenarios and submit questions directly to the panel for their consideration. Discussion topics include:
11:00 a.m. - 2:00 p.m. Pacific timeCase Discussion 1: Early Treatment for High-Risk Smoldering MM
Case Discussion 2: Individualized Approaches to Frontline Treatment Selection
Case Discussion 3: Managing the Patient With Relapsed Disease After = 1 Lines of Therapy
Case Discussion 4: Understanding the Different Anti-BCMA Therapies
Panel Discussion: Future Directions and a New 2021 Treatment Algorithm for MM
On demand content can be found by the link below, and will be posted through end of day (11:59 p.m. PST) Friday, March 19. For program questions, please contact: meetings@clinicaloptions.com
Chair:
Brian G.M. Durie, MD
Cedars Sinai Cancer Center
Los Angeles, CASpeakers:
Shaji K. Kumar, MD
Mayo Clinic Rochester, Division of Hematology
Rochester, MNThomas Martin, MD
University of California
San Francisco, CAPhilippe Moreau, MD
Nantes University Hospital
Nantes, FranceS. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MNJesús F. San-Miguel
University of Navarra
Pamplona, SpainClinical Care Options , Clinical Care Options, LLC
Email: meetings@clinicaloptions.comAdvances in Therapy for Inherited Non-Malignant Blood Disorders: Focus on Sickle Cell Disease and Hemophilia.
This program is supported by an educational grant from Novo Nordisk Inc. This continuing medical education activity is provided by Vindico Medical Education.
Friday, December 04, 2020
This continuing medical education symposium will address continuing and emerging educational needs in the care and management of patients with sickle cell disease or hemophilia. Experts in the field will provide didactic presentations and panel discussion on these rare non-malignant blood orders to address the tremendous burden of disease that occurs in these patients and provide guidance to integrate current and emerging management strategies into the clinic to enhance patient care and quality of life. The safety and efficacy of recent therapeutic advances will also be evaluated to provide insight into their integration into the treatment decision process and to ensure optimal, individualized patient care.
11:00 a.m. - 2:00 p.m. Pacific timeOn demand content can be found by the link below, and will be posted through end of day (11:59 p.m. PST) Friday, March 19. For program questions, please contact: CME@VindicoCME.com
Chair:
Steven W. Pipe, MD
University of Michigan
Ann Arbor, MISpeakers:
Biree Andemariam, MD
University of Connecticut
Farmington, CTChristine Guelcher, Hemostasis RN-BC, MS, PPCNP-BC
Center for Cancer and Blood Disorders
Washington, DCMark Reding, MD
University of Minnesota Medical Center
Minneapolis, MNCME Resource , Vindico Medical Education
Email: CME@VindicoCME.comBuilding New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutics in FL and DLBCL
This program is supported by educational grants from ADC Therapeutics, Epizyme Inc., Incyte Corporation, Kite, A Gilead Company, and MorphoSys US Inc.
Friday, December 04, 2020
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are two of the more common non-Hodgkin lymphomas (NHLs); these aggressive and indolent disorders represent the two classic “faces” of lymphoma. Recently, several novel therapeutic classes, including targeted agents, next-generation antibodies, and CAR-T cell therapy, have emerged as active strategies in diverse DLBCL and FL settings. These developments have challenged the use of standard immunochemotherapy-focused management and led to a new era of care in which increasingly, baseline factors can help identify patients who may benefit from the use of innovative therapeutics.
11:00 a.m. - 2:00 p.m. Pacific timeThis live web broadcast will provide learners with a clinical grounding on how new science is changing FL and DLBCL management. Each scientific seminar will open with a case-based “Tumor Board” session that will explore important factors in the selection and use of newer therapeutics, followed by a concise expert take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive NHL. Register today to learn how the experts are rising to the challenge of modern patient management for aggressive and indolent NHL. Don’t miss this informative event!
On demand content can be found by the link below, and will be posted through end of day (11:59 p.m. PST) Friday, March 19. For program questions, please contact: Questions@PeerView.com
Chair:
Nathan H. Fowler, MD
The University of Texas MD Anderson Cancer Center
Houston, TXSpeakers:
Prof. Dr. Martin Dreyling, MD
LMU Hospital
Munich, GermanyCaron Jacobson, MD, MMSc
Harvard Medical School
Boston, MAKrish Patel, MD
Swedish Cancer Institute
Seattle, WAPVI Live , PeerView Institute for Medical Education
Email: Questions@PeerView.comConsensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Chronic Lymphocytic Leukemia (Part 2 of a 4-Part Series)
This program is supported by AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC
Friday, December 04, 2020
This activity, the second of a 4-part live webinar series, will feature 5 chronic lymphocytic leukemia (CLL) investigators serving as the faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to the live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions and scenarios related to the management of CLL. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.
11:00 a.m. - 2:00 p.m. Pacific timeFor more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.
On demand activity expected to be available here mid-January 2021.
Chair:
Neil Love, MD
Research To Practice
Miami, FLSpeakers:
Paul M. Barr, MD
Medical Director, Clinical Trial Office, Professor of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center
Rochester, NYMatthew S. Davids, MD
Harvard Medical School
Boston, MAKerry A. Rogers, MD
The Ohio State University
Columbus, OHTanya Siddiqi, MD
City of Hope Cancer Center
Duarte, CAStephan Stilgenbauer, Professor Dr
Saarland University Medical Center
Homburg, GermanySylvia Eriksen , Research To Practice
Email: bmoss@researchtopractice.com3
Late Afternoon Symposia
3:00 p.m. - 6:00 p.m.
Pacific timeAdopting New Approaches for Relapsed/Refractory Follicular Lymphoma
This program is supported by an independent educational grant from Epizyme, Inc.
Friday, December 04, 2020
Join us for Trivia Night! Compete against your peers through case-based challenges about relapsed/refractory follicular lymphoma. Test your skills selecting treatment and managing side effects as well as your knowledge of novel and emerging therapies. This will be a lively symposium with panel discussion and clinical pearls.
3:00 p.m. - 6:00 p.m. Pacific timeOn demand activity expected to be available here on January 15, 2021. For program questions, please contact: jharden@medscapelive.com
Chair:
Loretta J. Nastoupil, MD
The University of Texas MD Anderson Cancer Center
Houston, TXSpeakers:
Connie Lee Batlevi, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NYMatthew A. Lunning, DO, FACP
University of Nebraska Medical Center
Omaha, NEJaye Harden , MedscapeLIVE!
Email: jharden@medscapelive.comApplying Data to Practice: The Role of BTK Inhibitors for the Treatment of CLL
This program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP.
Friday, December 04, 2020
Join us for this interactive, case-based, symposium where you can test your knowledge and skills using BTK inhibitors for the treatment of patients with treatment-naïve and relapsed/refractory CLL. Using a tumor board approach, the panel will discuss real-world examples and will put the trial data for BTK inhibitors into clinical context. The audience will vote on treatment choices for patients and how they would manage treatment-related side effects. The panel will discuss best practices for recognizing and mitigating side effects of BTK inhibitors. The symposium will also include future directions for BTK inhibitors, such as novel agents and investigational combinations.
3:00 p.m. - 6:00 p.m. Pacific timeOn demand activity expected to be available here on January 15, 2021. For program questions, please contact: jharden@medscapelive.com
Chair:
Jennifer Woyach, MD
The Ohio State University, Comprehensive Cancer Center
Columbus, OHSpeakers:
John N. Allan, MD
Weill Cornell Medicine
New York, NYDeborah M. Stephens, DO
University of Utah/Huntsman Cancer Institute
Salt Lake City, UTJaye Harden , MedscapeLIVE!
Email: jharden@medscapelive.comConsensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Acute Myeloid Leukemia (Part 3 of a 4-Part Series)
This program is supported by Abbvie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo, Genentech, a member of the Roche Group, Helsinn Healthcare SA and Pfizer Inc
Friday, December 04, 2020
This activity, the third of a 4-part live webinar series, will feature 5 acute myeloid leukemia (AML) investigators serving as faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions and scenarios related to the management of AML. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.
3:00 p.m. - 6:00 p.m. Pacific timeFor more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.
On demand activity expected to be available here mid-January 2021.
Chair:
Neil Love, MD
Research To Practice
Miami, FLSpeakers:
Mark Levis, MD, PhD
Director, Adult Leukemia Program, Co-Division Director, Hematologic Malignancies, Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine
Baltimore, MDAlexander E. Perl, MD
University of Pennsylvania
Philadelphia, PADaniel A. Pollyea, MD
University of Colorado Denver
Aurora, COEytan M. Stein, MD
Memorial Sloan Kettering Cancer Center
New York, NYAndrew H Wei, MBBS, PhD
The Alfred Hospital
Melbourne, AustraliaSylvia Eriksen , Research To Practice
Email: bmoss@researchtopractice.comEvolving the Standard of Care: Rethinking the Treatment Paradigm for Iron Deficiency Anemia
This program is supported by an independant educational grant from Pharmacosmos Therapeutics, Inc.
Friday, December 04, 2020
Iron deficiency anemia (IDA) continues to be a significant public health burden leading to a number of adverse health outcomes. Although oral iron is traditionally viewed as fist-line therapy, this is largely due to perceived safety issues with older intravenous (IV) iron formulations. Newer IV iron formulations show comparable efficacy and safety to oral agents, which may present a more convenient and cost-effective treatment option for the management of IDA.
3:00 p.m. - 6:00 p.m. Pacific timeJoin our panel of top experts for an interactive, virtual, CME-certified symposium providing up-to-date information for the treatment of iron deficiency anemia, including the pathophysiology of IDA in order to accurately identify and diagnose patients at increased risk. The efficacy and safety of different iron replacement formulations will also be discussed to inform the selection of the appropriate therapy to optimize the management of patients.?
On demand activity expected to be available here on January 15, 2021. For program questions, please contact: jharden@medscapelive.com
Chair:
Carlo Brugnara, MD
Harvard Medical School, Boston Children's Hospital
Boston, MASpeakers:
Michael Auerbach, MD, FACP
Auerbach Hematology and Oncology
Baltimore, MDMyles Wolf, MD, MMsc
Duke University School of Medicine
Durham, NCJaye Harden , MedscapeLIVE!
Email: jharden@medscapelive.comExperts Debate Optimal Approaches to the Treatment of Multiple Myeloma
This program is supported by GlaxoSmithKline, Janssen, Oncopeptides
Friday, December 04, 2020
Clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients. This live streamed educational symposium will involve 4 world renowned experts actively engaged in the management of patients with Multiple Myeloma. Join us and listen to the experts debate the most pressing topics in MM. Polling questions, short didactic sessions, and Q&A opportunities will also be provided. Don’t forget to visit BioAscend.com to view an accredited videotaped discussion highlighting the most clinically relevant data presented which will be available 4 to 6 weeks after the symposium.
3:00 p.m. - 6:00 p.m. Pacific timeOn demand activity available here until January 28 at 11:59 p.m. PST. For program questions, please contact: dunnam@bioascend.com
Chair:
Sagar Lonial, MD
Winship Cancer Institute of Emory University
Atlanta, GASpeakers:
Kenneth Anderson, MD
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
Boston, MAPieter Sonneveld, MD, PhD
Department of Hematology, Erasmus MC Cancer Institute
Rotterdam, NetherlandsPeter Voorhees, MD
Levine Cancer Institute, Atrium Health
Charlotte, NCChloe Dunnam , Bio Ascend
Email: dunnam@bioascend.com4
Evening Symposia
7:00 p.m. - 10:00 p.m.
Pacific timeConsensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Hodgkin and Non-Hodgkin Lymphoma (Part 4 of a 4-Part Series)
This program is supported by AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics Inc and Seattle Genetics
Friday, December 04, 2020
This activity, the fourth of a 4-part live webinar series, will feature 5 lymphoma investigators serving as faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to live webinar, the faculty plus 3 other investigators will complete a pre-survey to ascertain their perspectives on controversial questions/scenarios related to the management of Hodgkin and NHL, including FL, mantle cell and DLBCL. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.
7:00 p.m. - 10:00 p.m. Pacific timeFor more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.
On demand activity expected to be available here mid-January 2021.
Chair:
Neil Love, MD
Research To Practice
Miami, FLSpeakers:
Jonathan W. Friedberg, MD, MSSc
James P. Wilmot Cancer Center
Rochester, NYJohn Kuruvilla, MD
Princess Margaret Cancer Centre
Toronto, CanadaAnn S. LaCasce, MD, MSc
Dana-Farber Cancer Institute
Boston, MAJohn P. Leonard, MD
Weill Cornell Medical College
Pelham Manor, NYMichael E. Williams, MD
University of Virginia Health System
Charlottesville, VASylvia Eriksen , Research To Practice
Email: bmoss@researchtopractice.comImproving Outcomes in MDS and MPN: Tailoring Treatment Based on Patient- and Disease-Specific Factors
This program is supported by educational grants from Agios Pharmaceuticals, Inc.; Astex Pharmaceuticals, Inc.; Bristol Myers Squibb; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; Taiho Oncology, Inc.; and Takeda Oncology
Friday, December 04, 2020
This live program is designed to update physicians on the latest advancements in the clinical management of MDS and MPNs, including current approaches, diagnostic strategies, anemia management, and novel therapies under investigation for these diseases. In addition, this program will use case studies to apply recent findings to real-world case scenarios and will allow participants to reflect on how they might handle each scenario.
7:00 p.m. - 10:00 p.m. Pacific timeOn demand content can be found by the link below, and will be posted through end of day (11:59 p.m. PST) March 19. For program questions, please contact: dkleinstein@gotoper.com
Chair:
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, TXSpeakers:
Ruben Mesa, MD
UT Health San Antonio Cancer Center
San Antonio, TXValeria Santini
AOU Careggi-University of Florence
Firenze, Fi, ItalyAyalew Tefferi, MD
Mayo Clinic
Rochester, MNDayna Kleinstein , Physicians' Education Resource® (PER®)
Email: info@gotoper.com